also contributes to disease. Striatal medium-sized spiny projection neurons (SPNs) of the caudate and putamen are first affected and most extensively degenerate in HD. 7, 8 Other brain areas, including the neocortex and hippocampus, are impacted also, particularly in later stages. Interestingly, although HTT is widely expressed, many brain areas such as the cerebellum are largely spared. 8 Even within the striatum, cholinergic and aspiny interneurons are relatively unaffected. 9, 10 The reasons underlying this relatively selective striatal SPN vulnerability are incompletely understood.
Although HD's genetic underpinnings are well defined, the precise mechanisms linking protein alteration to symptomatology and underlying neurodegeneration remain unclear. Complicating matters,
wHTT's normal function is still incompletely understood. However, its large size (347 kD) and multiple protein-protein interaction sites suggest a scaffolding role, 11 which is supported by its large protein interactome. 12 Mutant huntingtin's polyglutamine expansion causes it to form amyloid-like aggregates, seen as cytoplasmic and intranuclear inclusions, but also facilitates interactions with proteins possessing similar domains. 13, 14 A quantitative proteomic analysis suggests that 200
proteins preferentially associate with mutant vs WT HTT. Conversely, mHTT's altered conformation impedes 149 normal WT protein interactions. 14 Therefore, despite HD's monogenic origins, mechanisms underlying neurodegeneration are likely multifactorial.
Disordered neuronal Ca 2+ signaling is a recurrent finding in the HD literature, observed across multiple model systems. 15 This takes many forms and, in in vitro models, sensitizes striatal SPNs to Ca 2+ -mediated apoptosis. Synaptic plasticity is also intimately linked to Ca 2+ -dependent processes 16 and is likewise aberrant in HD models, 17 preceding frank neuronal loss. Importantly, animal models support the disease-modifying potential of treatments targeting some aspects of deranged Ca 2+ handling. Aside from directly targeting mHTT, we argue Ca
2+
-dependent processes present some of the most promising therapeutic targets and might additionally prove useful for treating more common neurodegenerative disorders such as Alzheimer's and
Parkinson's disease. 15 Mutant huntingtin is expressed throughout development, while symptomatic onset is relatively late in life; this provides ample opportunity for compensatory processes to occur. A major challenge thus becomes discerning root pathology from compensation, particularly when considering the myriad of documented mHTT-mediated effects on neuronal function. The principle focus of this review will be highlighting mHTT-mediated alterations in neuronal Ca 2+ handling with an emphasis on discerning causation from compensatory processes.
Rodent HD models have been instrumental in addressing these questions, including transgenic mice expressing fragments of mHTT (eg, R6/2, R6/1) or full-length mHTT (using yeast or bacterial artificial chromosomes-YAC and BAC models, respectively) and mice in which the CAG expansion is knocked in to the murine HTT gene; we direct the reader to the following publications for comprehensive reviews of prominent HD animal models. 18, 19 As attention will be given to those alterations seen early in the disease process, much of the evidence reviewed is from the YAC transgenic mouse model, which shows slow progression allowing for investigation of disease mechanisms involved in synaptic and neuronal dysfunction preceding neurodegeneration.
Additionally, emphasis will be placed on mechanisms whose inhibition reverses or prevents disease progression in animals and on highlighting molecular interactions between mHTT and affected cellular processes. Finally, we strive to identify current knowledge gaps meriting further investigation. 
| ER CA

| NMDA RECEPTORS
Aberrant N-methyl-D-aspartate receptor (NMDAR) signaling has long been causally implicated in HD. Indeed, intrastriatal injections of the NMDAR agonist quinolinic acid were used as a chemical model of HD and largely recapitulate the motor deficits and histological hallmarks of HD in rodents and nonhuman primates. 33, 34 Functional N-methyl D-aspartate receptors (NMDARs) are heterotetramers typically containing two GluN1 and two GluN2 subunits. 35 Eight distinct GluN1 isoforms and four GluN2 types (A-D) exist, which variably combine, creating numerous functionally distinct NMDARtypes. Additionally, a third GluN3 subunit class incorporates into some NMDARs, modulating Ca 2+ permeability and Mg 2+ block. 36 Glutamate binds the GluN2 subunit, while the GluN1 and GluN3 subunits bind the obligatory coagonists D-serine or glycine. [41] [42] [43] This dichotomy is reflected at the molecular level in opposing effects on nuclear CREB, which is phosphorylated and activated following synaptic NMDAR signaling but dephosphorylated by extrasynaptic NMDAR activation. 44 Importantly, mHTT-expressing striatal SPNs are more vulnerable to glutamate-mediated toxicity. 45 This appears to be due to enhanced NMDAR currents, seen in SPNs in a variety of HD models. 46 Furthermore, NMDAR current density correlates with the mHTT polyglutamine repeat length in the transgenic YAC mouse model. 47 Enhanced NMDAR currents appear to be largely mediated by GluN2B subunit-containing NMDARs, which are preferentially extrasynaptic in adult neurons. Indeed, brain slice electrophysiology experiments strongly suggest the selective enhancement of extrasynaptic GluN2B-containing NMDAR currents in striatal SPNs of YAC128 mice; here, evoked NMDAR currents were only greater than those in WT or YAC18 control at high stimulation intensities, conditions expected to cause extrasynaptic glutamate spillover. 48 Enhanced extrasynaptic
NMDARs were also reported in striatal SPNs from other HD mouse models, 49 but whether this change is present in striatal interneurons is unknown. Furthermore, striatal extracts from YAC128 mice show decreased nuclear CREB activity, consistent with enhanced extrasynaptic NMDAR signaling in vivo. 48 YAC128 and YAC72 SPNs show enhanced surface expression of GluN2B-containing NMDARs, which localize to extrasynaptic membranes. 47, 48, 50 However, total striatum expression of these proteins is similar in YAC46, YAC72, YAC128, and WT littermates. 51, 52 Thus, increased surface GluN2B expression is not driven by enhanced protein synthesis, but rather appears to be due to higher rates of ER to cell surface export in YAC72 mice (where this question was investigated). 47 Interestingly, YAC72 SPNs also show enhanced endocytic removal of cell surface GluN1-GluN2B-containing The above speaks compellingly to causation, however definitive proof requires mitigating HD pathology by blocking excessive extrasynaptic NMDAR activation. The current lack of perfectly selective pharmacological tools, however, makes this practically challenging.
The best evidence thus far is provided by studies using memantine, a preferential extrasynaptic NMDAR blocker at low doses. 59 Early low-dose memantine treatment improved behavioral and histological pathology in YAC128 mice 48, 60 and normalized nuclear CREB function. 48, 61 Conversely, high-dose memantine, which also blocks synaptic NMDARs, was detrimental. 60 Antagonists selective for GluN2B subunit-containing NMDARs are available and therefore might achieve a relatively selective extrasynaptic receptor blockade. Indeed, the GluN1-GluN2B-specific antagonist ifenprodil largely blocked NMDAmediated apoptosis in YAC72, YAC128, and WT SPN cultures. 26, 45 However, some GluN1-GluN2B receptors are synaptic, the blockade of which might negatively impact neuronal health. Importantly, the above striatal SPN cultures lacked cortical neurons and therefore had no trophic glutamatergic input to be blocked. 60 Increased mHTT aggregation formation improved cell survival despite the persistence of enhanced extrasynaptic NMDAR currents;
however, extrasynaptic NMDAR activation caused mHTT disaggregation. 60 These findings suggest that enhanced synaptic NMDAR activation, by sequestering toxic mHTT oligomers into aggregates, facilitates a beneficial compensation against enhanced extrasynaptic NMDAR activity.
| MITOCHONDRIA
Mitochondria play a fundamental role in translating increased cy- Cytosolic cytochrome C release is greatly enhanced in cultured YAC128 SPNs exposed to a 250 μmol/L glutamate challenge and parallels increased apoptotic cell death in these neurons. 26 Apoptosis rates in this model were restored to WT levels when mitochondrial Ca 2+ uptake was prevented with the mitochondria uniporter blocker ruthenium 360. Blocking the permeability transition pore and mitochondrial-dependent caspase activation similarly normalized apoptosis. 26, 45 R6/2 mice show increased cytosolic cytochrome C levels in vivo. 71 In addition, minocycline, an antibiotic that prevents mitochondrial release of prodeath molecules including cytochrome C, 72, 71 increased R6/2 mouse survival time. 73 Beyond simply responding to increased cytosolic Ca proportionate. 74 SPNs from symptomatic R6/2 mice show depolarized resting membrane potentials, likely partly mediated by mitochondrial dysfunction. 83 Moreover, rodent models suggest mHTT directly modulates permeability transition pore gating, causing opening and cytochrome C release at lower Ca 2+ concentrations 77.84 Reduced Ca 2+ uptake capacity has also been reported in mitochondria from YAC72 mice. 78 Despite the above evidence, an exhaustive set of studies by Nickolay Brustovetsky's group, using multiple mouse HD models, failed to observe any metabolic or Ca 2+ handling abnormalities in SPNderived mitochondria. 75, 76, 85 These studies mainly relied on isolated mitochondria, suggesting other cellular constituents might be required to reveal mHTT-mediated mitochondrial dysfunction. Consistent with this, several mitochondrial-related abnormalities, including reduced ATP/ADP ratios, mitochondrial depolarization, and increased Ca 2+ content, were exacerbated by exogenous NMDA applications in HD 106 Clinical HD pridopidine trials suggest its use in the management of some motor symptoms, but failed to show cognitive improvements. [107] [108] [109] Modest improvements in human trials contrast with animal model findings, but might be accounted for by the time point of the intervention. Clinical trials administered pridopidine to symptomatic, diagnosed HD patients, at which point neurodegeneration has typically progressed for more than 10 years before a diagnosis ( 110 see Fig 3) . We suggest that trials directing pridopidine treatment toward premanifest HD gene mutation carriers (based on predictive genetic testing) are more likely to address diseasemodifying potential.
Alternatively, agents blocking downstream effects of enhanced IP3R activity such as the enhanced SOC response (see above) might prove to be useful HD treatments. 27 Although pharmacological blockers of the SOC response in SPNs are available, 27, 28 greater preclinical work is likely needed to validate this treatment approach.
| Memantine and Other Modulators of NMDAR Signaling
HD animal models suggest blocking enhanced extrasynaptic NMDAR signaling is neuroprotective (see above). However, as yet there are no reports of randomized, placebo-controlled low-dose memantine studies in HD patients. Some pilot clinical studies suggest benefit, but these are not definitive. 111, 112 As with pridopidine, those studies were restricted to symptomatic patients. By contrast, animal studies initiated treatment at early, largely asymptomatic stages. Indeed, enhanced NMDAR signaling may be a first step in a larger pathological cascade of events. If so, blocking extrasynaptic NMDARs might be futile at late disease stages. Supporting this idea, GluN2B-containing NMDARs may be downregulated in late-stage HD, as compensation for persistently elevated extrasynaptic receptor signaling. In YAC128 mice calpain-mediated GluN2B-containing receptor cleavage significantly reduces total striatum GluN2B protein expression, 52 an effect that is progressive with age and disease stage.
| CONCLUSIONS
In pursuing a mechanistic, cause-based understanding of mHTTinduced pathology, our ultimate goal is to translate these insights into novel disease-modifying therapies, a currently unmet need. Agents that normalize the disrupted Ca 2+ handling (outlined above) show particular promise. It will be critical to target physiological processes causally related to disease progress, otherwise disrupting beneficial compensations might hasten disease progression. Greater benefit will likely also be derived from early interventions, prior to large-scale neuronal loss. A lack of early diagnostic markers makes this impractical in most neurodegenerative disorders; however, identifying HD patients before symptom onset is feasible given the relative ease of genetic testing.
